Cargando…

Impact of micro‐ and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study

BACKGROUND: The key goals of management in patients with type 2 diabetes (T2D) are to prolong life and improve quality of life. Micro‐ and macrovascular complications of T2D not only increase the risk of morbidity and mortality, but cross‐sectional studies indicate they may also worsen quality of li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnold, Suzanne V., Khunti, Kamlesh, Tang, Fengming, Chen, Hungta, Nicolucci, Antonio, Gomes, Marilia B., Ji, Linong, Shestakova, Marina V., Watada, Hirotaka, Cooper, Andrew, Fenici, Peter, Hammar, Niklas, Medina, Jesús, Kosiborod, Mikhail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917866/ https://www.ncbi.nlm.nih.gov/pubmed/35029066 http://dx.doi.org/10.1002/edm2.321

Ejemplares similares

Glycaemic control in patients with type 2 diabetes initiating second‐line therapy: Results from the global DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2019)

Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2020)

Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
por: Bongaerts, Brenda, et al.
Publicado: (2021)

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Type 2 diabetes and heart failure: insights from the global DISCOVER study
por: Arnold, Suzanne V., et al.
Publicado: (2021)

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: Results from the global DISCOVER study programme
por: Nicolucci, Antonio, et al.
Publicado: (2019)

Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study
por: Patel, Krishna K., et al.
Publicado: (2020)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study
por: Gomes, Marília B., et al.
Publicado: (2022)

Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study
por: Malik, Ali O., et al.
Publicado: (2022)

Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study
por: Charbonnel, Bernard H., et al.
Publicado: (2022)

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry(®)
por: Arnold, Suzanne V., et al.
Publicado: (2017)

Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014
por: Caspard, Herve, et al.
Publicado: (2017)

Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink
por: Wilding, John, et al.
Publicado: (2018)

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
por: Kosiborod, Mikhail, et al.
Publicado: (2017)

Methods and rationale of the DISCOVER CKD global observational study
por: Pecoits-Filho, Roberto, et al.
Publicado: (2021)

Eligibility of patients with type 2 diabetes for sodium‐glucose co‐transporter‐2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry
por: Wittbrodt, Eric, et al.
Publicado: (2019)

Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes
por: Palladino, Raffaele, et al.
Publicado: (2020)

Long COVID — metabolic risk factors and novel therapeutic management
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Real-World Data on the Incidence of Macrovascular Complications in Japanese Patients with Type 2 Diabetes: The Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project
por: Ohmura, Hirotoshi, et al.
Publicado: (2019)

Early aggressive macrovascular disease and type 1 diabetes mellitus without chronic complications: a case report
por: Saldanha de Mattos Matheus, Alessandra, et al.
Publicado: (2013)

All‐cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK
por: Ling, Suping, et al.
Publicado: (2022)

Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan—A Protocol
por: Katakami, Naoto, et al.
Publicado: (2017)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Macrovascular Complications in Patients with Diabetes and Prediabetes
por: Huang, Dou, et al.
Publicado: (2017)

Endothelium in Coronary Macrovascular and Microvascular Diseases
por: Godo, Shigeo, et al.
Publicado: (2021)

When Manual Analysis of 12-Lead ECG Holter Plays a Critical Role in Discovering Unknown Patterns of Increased Arrhythmogenic Risk: A Case Report of a Patient Treated with Tamoxifen and Subsequent Pneumonia in COVID-19
por: Brisinda, Donatella, et al.
Publicado: (2021)

The association between macrovascular complications and intensive care admission, invasive mechanical ventilation, and mortality in people with diabetes hospitalized for coronavirus disease-2019 (COVID-19)
por: Llauradó, Gemma, et al.
Publicado: (2022)

Role of Endoplasmic Reticulum Stress in Atherosclerosis and Diabetic Macrovascular Complications
por: Chistiakov, Dmitry A., et al.
Publicado: (2014)

Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
por: Kohsaka, Shun, et al.
Publicado: (2020)

Heart in Diabetes: Not Only a Macrovascular Disease
por: Stratmann, Bernd, et al.
Publicado: (2011)

Type 2 Diabetes Mellitus and Macrovascular Complications
por: Shan, Peng-Fei, et al.
Publicado: (2017)

Genetics of macrovascular complications in type 2 diabetes
por: Tonyan, Ziravard N, et al.
Publicado: (2021)

Greater macrovascular and microvascular morbidity from type 2 diabetes in northern compared with southern China: A cross‐sectional study
por: Wang, Li, et al.
Publicado: (2020)

Proteasome modulator 9 and macrovascular pathology of T2D
por: Gragnoli, Claudia
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_s0cosf2m5ls5q0mcovt2r2p29f